By Andrew Silver July 8 (Reuters) - AstraZeneca will pay a subsidiary of Sino Biopharmaceutical $200 million upfront for the ...

Jet2 unveils buyback and top-end profits Jet2 has announced a £250 million share buyback as profits came in at the top of its ...

Sino Biopharmaceutical has struck a licensing deal with AstraZeneca for a chronic respiratory disease treatment and obtained commercialization rights for two GSK treatments in China, as global ...

Sino Biopharmaceutical inks a licensing deal with AstraZeneca for a respiratory drug, with milestones and royalties worth ...

Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.

AstraZeneca struck a licensing deal for a chronic respiratory disease treatment with Sino Biopharmaceutical that could be valued at up to $1.9 billion, sending shares in the Chinese drugmaker sharply ...

By Andrew Silver July 8 (Reuters) - AstraZeneca will license a subsidiary of Sino Biopharmaceutical's experimental chronic ...

July 8 () - Hong Kong-listed Sino Biopharmaceutical said on Wednesday ‌it has granted AstraZeneca ‌the rights to develop a ...

Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...